Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3284-3294

  Garonzik, S M ^a   Li, J ^a,b   Thamlikitkul, V ^c   Paterson, D L ^d   Shoham, S ^e   Jacob, J ^b   Silveira, F P ^f   Forrest, A ^a   Nation, R L ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b MONASH UNIVERSITY   (Australia)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e WASHINGTON HOSPITAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; CREATININE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE CLEARANCE; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG CLEARANCE; FEMALE; GRAM NEGATIVE INFECTION; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79959248672     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01733-10     Document Type: Article

References (33)

1. Antoniadou, A., et al. 2007. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother. 59:786-790.
2. APP Pharmaceuticals LLC. 2008. Colistimethate. Package insert. APP Pharmaceuticals LLC, Schaumburg, IL.
3. Bauer, R. J., S. Guzy, and C. Ng. 2007. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J. 9:E60-E83.
4. Bayard, D. S., M. H. Milman, and A. Schumitzky. 1994. Design of dosage regimens: a multiple model stochastic control approach. Int. J. Biomed. Comput. 36:103-115.
5. Beal, S. L. 2001. Ways to fit a PK model with some data below the quanti- fication limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
6. Beno, P., V. Krcmery, and A. Demitrovicova. 2006. Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clin. Microbiol. Infect. 12:497-498.
7. Bergen, P. J., J. Li, C. R. Rayner, and R. L. Nation. 2006. Colistin methane-sulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1953-1958.
8. Bulitta, J. B., A. Bingölbali, and C. B. Landersdorfer. 2010. Development and evaluation of a new efficiency tool (SADAPT-TRAN) for model creation, debugging, evaluation, and automated plotting using parallelized SADAPT, Perl and R, abstr. 1917. 19th Population Approach Group in Europe, Berlin, Germany.
9. D'Argenio, D. Z., A. Schumitzky, and X. Wang. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
10. Deryke, C. A., A. J. Crawford, N. Uddin, and M. R. Wallace. 2010. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob. Agents Chemother. 54:4503-4505.
11. Dudhani, R. V., R. L. Nation, and J. Li. 2010. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J. Antimicrob. Chemother. 65:1412-1415.
12. Dudhani, R. V., et al. 2010. Elucidation of the pharmacokinetic/ pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob. Agents Chemother. 54:1117-1124.
13. Dudhani, R. V., J. D. Turnidge, R. L. Nation, and J. Li. 2010. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J. Antimicrob. Chemother. 65:1984-1990.
14. Falagas, M. E., and S. K. Kasiakou. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341.
15. Garonzik, S. M., et al. 2010. Colistin PK model in patients with end-stage renal or liver disease. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1666.
16. Hartzell, J. D., et al. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48:1724-1728.
17. Jansson, B., M. Karvanen, O. Cars, D. Plachouras, and L. E. Friberg. 2009. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J. Pharm. Biomed. Anal. 49:760-767.
18. Jelliffe, R. 2002. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am. J. Nephrol. 22:320-324.
19. Jones, R. N. 2001. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119:397S-404S.
20. Ko, K. S., et al. 2007. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 60:1163-1167.
21. Li, J., et al. 2001. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 761:167-175.
22. Li, J., et al. 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob. Agents Chemother. 46:3304-3307.
23. Li, J., et al. 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother. 53:837-840.
24. Li, J., et al. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob. Agents Chemother. 47:1766-1770.
25. Li, J., R. L. Nation, R. W. Milne, J. D. Turnidge, and K. Coulthard. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25.
26. Li, J., et al. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
27. Li, J., et al. 2005. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob. Agents Chemother. 49:4814-4815.
28. Marchand, S., et al. 2010. Removal of colistin during intermittent haemodialysis in two critically ill patients. J. Antimicrob. Chemother. 65:1836-1837.
29. Markou, N., et al. 2008. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gramnegative bacilli infections: a prospective, open-label, uncontrolled study. Clin. Ther. 30:143-151.
30. Opal, S. M., and T. Calandra. 2009. Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients? JAMA 302:2367-2368.
31. Plachouras, D., et al. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother. 53:3430-3436.
32. Ratjen, F., et al. 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57:306-311.
33. Talbot, G. H., et al. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.